Bisphosphonates for osteoporosis
- 1 September 2001
- journal article
- review article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 39 (9) , 68-72
- https://doi.org/10.1136/dtb.2001.39968
Abstract
One in three women and at least one in 12 men in the UK have osteoporosis, a condition which can lead to fractures, deformity, pain and disability, at a cost to the NHS of around 1.5 billion Pounds each year. Bisphosphonates offer a therapeutic option for preventing and treating osteoporosis. Here, we assess and compare the three bisphosphonates (alendronate, etidronate and risedronate) licensed for such use in the UK. We do not consider the four bisphosphonates (clodronate, pamidronate, tiludronate and zoledronate) that are licensed in the UK only for the treatment of Paget's disease of bone and/or hypercalcaemia of malignancy.Keywords
This publication has 21 references indexed in Scilit:
- A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.Osteoporosis International, 2001
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosisArthritis & Rheumatism, 1999
- Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT StudyOsteoporosis International, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- A Four-Year Randomized Controlled Trial of Hormone Replacement and Bisphosphonate, Alone or in Combination, in Women with Postmenopausal OsteoporosisThe American Journal of Medicine, 1998
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996
- Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized studyThe American Journal of Medicine, 1995